Esperion (NASDAQ: ESPR) CLO trims 11,824 shares to pay RSU taxes

Rhea-AI Filing Summary

Esperion Therapeutics, Inc. Chief Legal Officer Benjamin Looker reported an open-market sale of 11,824 shares of common stock. The shares were sold at an average price of $3.155 per share to satisfy tax obligations on recently vested restricted stock units. After this transaction, he continues to hold 667,524 shares directly.

Insider Trade Summary

Net Seller: 11,824 shares ($37,305)

Net Sell 1 txn

Insider Looker Benjamin

Role Chief Legal Officer

Sold 11,824 shs ($37K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,824	$3.155	$37K

Holdings After Transaction: Common Stock — 667,524 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 11,824 shares Sale price: $3.155 per share Shares held after transaction: 667,524 shares

3 metrics

Shares sold 11,824 shares Open-market sale on 2026-06-17

Sale price $3.155 per share Average sale price for common stock

Shares held after transaction 667,524 shares Direct ownership following sale

Key Terms

open-market sale, restricted stock units, non-derivative, Chief Legal Officer

4 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

restricted stock units financial

"tax obligation on vested shares of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

non-derivative financial

""transaction_type": "non-derivative""

Chief Legal Officer financial

""officer_title": "Chief Legal Officer""

A chief legal officer is a senior executive responsible for overseeing a company's legal matters, ensuring that its activities comply with laws and regulations. They act like a company's legal guide, helping to prevent legal problems and manage risks. For investors, understanding this role is important because it reflects how well a company manages legal risks that could impact its stability and reputation.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Looker Benjamin

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		S		11,824(1)	D	$3.155	667,524	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ESPR Chief Legal Officer report?

Esperion Therapeutics Chief Legal Officer Benjamin Looker reported selling 11,824 common shares. The sale was conducted as an open-market transaction at an average price of $3.155 per share, according to the Form 4 insider filing for Esperion Therapeutics, Inc. (ESPR).

Why did Benjamin Looker sell Esperion Therapeutics (ESPR) shares?

The shares were sold to satisfy tax obligations on vested restricted stock units. This indicates the transaction was primarily related to covering tax liabilities associated with equity compensation rather than a discretionary portfolio reallocation decision, based on the footnote disclosure in the Form 4 filing.

How many Esperion Therapeutics shares did the CLO sell and at what price?

Benjamin Looker sold 11,824 shares of Esperion Therapeutics common stock. The reported average sale price was $3.155 per share in an open-market transaction, as disclosed in the Form 4 insider trading report filed for Esperion Therapeutics, Inc. (ESPR).

How many Esperion Therapeutics shares does Benjamin Looker hold after the sale?

Following the reported sale, Benjamin Looker directly holds 667,524 shares of Esperion Therapeutics common stock. This post-transaction figure in the Form 4 shows he retains a substantial equity position in Esperion Therapeutics, Inc. (ESPR) after covering tax obligations from vested restricted stock units.

Was the ESPR insider sale related to derivative or option exercises?

The Form 4 lists a non-derivative transaction in Esperion Therapeutics common stock, classified as an open-market sale. A footnote specifies the shares were sold to cover tax obligations on vested restricted stock units, rather than resulting from an option or derivative exercise event.